The 11th annual
Amsterdam Immunogenicity & Tolerance Seminar
November 7, 2025 | 8:30 am – 4:00 pm with reception to follow | The Hilton Apollolaan Hotel
Registration is now closed
About the Amsterdam Immunogenicity & Tolerance Seminar:
Now in its 11th year, the Amsterdam Immunogenicity and Tolerance (AIT) Seminar continues to unite leaders from industry, academia, and regulatory bodies to explore advances in immune tolerance and immunogenicity science.
This year’s program will feature talks spanning tolerance mechanisms, HLA and immunopeptidome analysis, and the role of regulatory immune cells in health and disease. Expect engaging discussions on Treg and Breg biology, immunogenicity risk assessment, and emerging approaches to monitoring immune responses — from novel MAPPS methodologies to soluble HLA peptidome profiling.
With speakers representing organizations such as Bayer, the European Medicines Agency (EMA), NHS, Leiden University Medical Center, the University of Liverpool, the Polish Academy of Sciences, Inmunotek, ImmuneSpec, and EpiVax, the seminar offers a unique, multidisciplinary perspective on the challenges and innovations shaping biologics and vaccine development.Join us in Amsterdam on November 7 for a full day of scientific exchange, poster presentations, and networking with colleagues advancing the science of tolerance and immunogenicity.
Organizing Committee:
Annie De Groot, M.D. Founder & Chief Medical Officer, EpiVax Inc.
Vibha Jawa, Ph.D. Chief Scientific Officer, EpiVax, Inc.
Corine Kruiswijk, Ph.D. Director, Translational Research, Intravacc
Marcel Hoefnagel, Ph.D. Senior Scientist/Assessor, College ter Beoordeling van Geneesmiddelen
Elly van Riet, Ph.D. Senior Scientist, TuBerculosis Vaccine Initiative
Femke Broere, Ph.D. Professor of Translational Immunology, Faculty of Veterinary Medicine, Utrecht University
Check out past year’s AIT Seminars:
2024 Amsterdam Immunogenicity & Tolerance Seminar
